Skip to content
Community, Medical Health Aged Care

Patients welcome better access to Shingrix® for immunocompromised patients

Better Access Australia and AusPIPS Inc < 1 mins read

Shingles is a painful and difficult disease, but the length and severity of the disease in immunocompromised people can often be compounded and exacerbate already complex health conditions.

AusPIP and BAA have been advocating for expanded access to Shingrix® after the 2023-24 federal budget funding decision limited access to only those “immunocompromised patients aged 18 years and over with: haemopoietic stem cell transplant; solid organ transplant; haematological malignancy; and advanced or untreated HIV.

This denied funded access to patients with common and complex immunocompromised need patients like those with primary and secondary immunodeficiency. It also denied access to patients with immune system vulnerabilities as a result of treatments for common chronic diseases such as diabetes, arthritis, chronic obstructive pulmonary disorder and multiple sclerosis without subsidised access.

From 30 August 2024 funded access to Shingrix® has been expanded to include anyone “18 years and over considered at increased risk of herpes zoster due to an underlying condition and/or immunosuppressive treatments

BAA and AusPIPs have welcomed the decision and issued the attached media release with comments from both organisations about the important first step this represents in modernising Australia's approach to adult vaccination and the important role it plays in preventative health  for adults particularly with the increasing use of treatment that impact the immune system as part of better chronic disease management.

Quotes for attribution and Quick facts attached in full press release. 


Key Facts:

This vaccine was listed on the ARTG 1950 days before it was subsidised on the National Immunisation Program 

#100days


About us:

AusPIPS Inc represents primary and secondary immunodeficient (PID SID) patients in Australia, and Better Access Australia works with patients groups to advocate for improved health, disability and social services in Australia.


Contact details:

BAA: fmcneill@betteraccessaustralia.org.au

AusPIPS president@auspips.org.au

Media

More from this category

  • Art, Community
  • 15/01/2025
  • 11:55
Arts in Greater Dandenong

Tiny Artworks, Big Impact

Arts in Greater Dandenong is delighted to announce the launch of the 9 by 5 Exhibition, an inspiring event that continues a legacy of…

  • Contains:
  • Medical Health Aged Care
  • 15/01/2025
  • 10:33
Monash University

The Lancet Diabetes & Endocrinology: Global Commission proposes major overhaul of obesity diagnosis, going beyond BMI to define when obesity is a disease.

A global Commission, published in The Lancet Diabetes & Endocrinology and endorsed by 75 medical organisations around the world [1], presents a novel, nuanced approach to diagnose obesity, based on other measures of excess body fat in addition to body mass index (BMI), and objective signs and symptoms of ill health at the individual level. The proposal is designed to address limitations in the traditional definition and diagnosis of obesity that hinder clinical practice and healthcare policies, resulting in individuals with obesity not receiving the care they need. By providing a medically coherent framework for disease diagnosis, the Commission also…

  • Medical Health Aged Care
  • 14/01/2025
  • 17:10
Galderma

Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss

Three-month interim data from first-of-its-kind trial demonstrate that the combination of Sculptra® and Restylane® Lyft™ or Contour™ effectively improved the facial aesthetic appearance of…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.